Top

Molecular Pain

Published in:

Open Access 01-12-2009 | Research

Antidepressants inhibit P2X₄ receptor function: a possible involvement in neuropathic pain relief

Authors: Kenichiro Nagata, Toshiyasu Imai, Tomohiro Yamashita, Makoto Tsuda, Hidetoshi Tozaki-Saitoh, Kazuhide Inoue

Published in: Molecular Pain | Issue 1/2009

Abstract

Background

Neuropathic pain is characterized by pain hypersensitivity to innocuous stimuli (tactile allodynia) that is nearly always resistant to known treatments such as non-steroidal anti-inflammatory drugs or even opioids. It has been reported that some antidepressants are effective for treating neuropathic pain. However, the underlying molecular mechanisms are not well understood. We have recently demonstrated that blocking P2X₄ receptors in the spinal cord reverses tactile allodynia after peripheral nerve injury in rats, implying that P2X₄ receptors are a key molecule in neuropathic pain. We investigated a possible role of antidepressants as inhibitors of P2X₄ receptors and analysed their analgesic mechanism using an animal model of neuropathic pain.

Results

Antidepressants strongly inhibited ATP-mediated Ca²⁺ responses in P2X₄ receptor-expressing 1321N1 cells, which are known to have no endogenous ATP receptors. Paroxetine exhibited the most powerful inhibition of calcium influx via rat and human P2X₄ receptors, with IC₅₀ values of 2.45 μM and 1.87 μM, respectively. Intrathecal administration of paroxetine produced a striking antiallodynic effect in an animal model of neuropathic pain. Co-administration of WAY100635, ketanserin or ondansetron with paroxetine induced no significant change in the antiallodynic effect of paroxetine. Furthermore, the antiallodynic effect of paroxetine was observed even in rats that had received intrathecal pretreatment with 5,7-dihydroxytryptamine, which dramatically depletes spinal 5-hydroxytryptamine.

Conclusion

These results suggest that paroxetine acts as a potent analgesic in the spinal cord via a mechanism independent of its inhibitory effect on serotonin transporters. Powerful inhibition on P2X₄ receptors may underlie the analgesic effect of paroxetine, and it is possible that some antidepressants clinically used in patients with neuropathic pain show antiallodynic effects, at least in part via their inhibitory effects on P2X₄ receptors.

Available only for authorised users

Sindrup SH, Otto M, Finnerup NB, Jensen TS: Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005, 96: 399–409. 10.1111/j.1742-7843.2005.pto_96696601.xPubMedCrossRef

Lynch ME: Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001, 26: 30–36.PubMedCentralPubMed

Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, Dubner R: Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987, 37: 589–596.PubMedCrossRef

Kvinesdal B, Molin J, Froland A, Gram LF: Imipramine treatment of painful diabetic neuropathy. Jama 1984, 251: 1727–1730. 10.1001/jama.251.13.1727PubMedCrossRef

Sindrup SH, Gram LF, Skjold T, Grodum E, Brosen K, Beck-Nielsen H: Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol 1990, 30: 683–691.PubMedCentralPubMedCrossRef

Max MB, Kishore-Kumar R, Schafer SC, Meister B, Gracely RH, Smoller B, Dubner R: Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991, 45: 3–9. discussion 1–2 10.1016/0304-3959(91)90157-SPubMedCrossRef

Sindrup SH, Tuxen C, Gram LF, Grodum E, Skjold T, Brosen K, Beck-Nielsen H: Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992, 43: 251–255. 10.1007/BF02333018PubMedCrossRef

Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J: Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982, 32: 671–673.PubMedCrossRef

Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH: Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988, 38: 1427–1432.PubMedCrossRef

10.

Kishore-Kumar R, Max MB, Schafer SC, Gaughan AM, Smoller B, Gracely RH, Dubner R: Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990, 47: 305–312.PubMedCrossRef

11.

Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, Royall RM, Max MB: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002, 59: 1015–1021.PubMedCrossRef

12.

Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992, 326: 1250–1256.PubMedCrossRef

13.

Jackson KC 2nd: Pharmacotherapy for neuropathic pain. Pain Pract 2006, 6: 27–33. 10.1111/j.1533-2500.2006.00055.xPubMedCrossRef

14.

Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF: The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990, 42: 135–144. 10.1016/0304-3959(90)91157-EPubMedCrossRef

15.

Baldessarini RJ: Drug therapy of depression and anxiety disorders. 11th edition. 2006.

16.

Reynolds IJ, Miller RJ: Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br J Pharmacol 1988, 95: 95–102.PubMedCentralPubMedCrossRef

17.

Watanabe Y, Saito H, Abe K: Tricyclic antidepressants block NMDA receptor-mediated synaptic responses and induction of long-term potentiation in rat hippocampal slices. Neuropharmacology 1993, 32: 479–486. 10.1016/0028-3908(93)90173-ZPubMedCrossRef

18.

Hall H, Ogren SO: Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol 1981, 70: 393–407. 10.1016/0014-2999(81)90172-2PubMedCrossRef

19.

Amir R, Argoff CE, Bennett GJ, Cummins TR, Durieux ME, Gerner P, Gold MS, Porreca F, Strichartz GR: The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain 2006, 7: S1–29. 10.1016/j.jpain.2006.01.444PubMedCrossRef

20.

Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT: Sodium Channel Blockade May Contribute to the Analgesic Efficacy of Antidepressants. J Pain 2007,8(4):315–24. Epub 2006 Dec 15 10.1016/j.jpain.2006.10.001PubMedCrossRef

21.

Huang CJ, Harootunian A, Maher MP, Quan C, Raj CD, McCormack K, Numann R, Negulescu PA, Gonzalez JE: Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential. Nat Biotechnol 2006, 24: 439–446. 10.1038/nbt1194PubMedCrossRef

22.

Traboulsie A, Chemin J, Kupfer E, Nargeot J, Lory P: T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. Mol Pharmacol 2006, 69: 1963–1968. 10.1124/mol.105.020842PubMedCrossRef

23.

Ishii Y, Sumi T: Amitriptyline inhibits striatal efflux of neurotransmitters via blockade of voltage-dependent Na+ channels. Eur J Pharmacol 1992, 221: 377–380. 10.1016/0014-2999(92)90726-KPubMedCrossRef

24.

Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K: P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003, 424: 778–783. 10.1038/nature01786PubMedCrossRef

25.

Marlier L, Teilhac JR, Cerruti C, Privat A: Autoradiographic mapping of 5-HT1, 5-HT1A, 5-HT1B and 5-HT2 receptors in the rat spinal cord. Brain Res 1991, 550: 15–23. 10.1016/0006-8993(91)90400-PPubMedCrossRef

26.

Hamon M, Gallissot MC, Menard F, Gozlan H, Bourgoin S, Verge D: 5-HT3 receptor binding sites are on capsaicin-sensitive fibres in the rat spinal cord. Eur J Pharmacol 1989, 164: 315–322. 10.1016/0014-2999(89)90472-XPubMedCrossRef

27.

Thor KB, Nickolaus S, Helke CJ: Autoradiographic localization of 5-hydroxytryptamine1A, 5-hydroxytryptamine1B and 5-hydroxytryptamine1C/2 binding sites in the rat spinal cord. Neuroscience 1993, 55: 235–252. 10.1016/0306-4522(93)90469-VPubMedCrossRef

28.

Bianchi BR, Lynch KJ, Touma E, Niforatos W, Burgard EC, Alexander KM, Park HS, Yu H, Metzger R, Kowaluk E, et al.: Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol 1999, 376: 127–138. 10.1016/S0014-2999(99)00350-7PubMedCrossRef

29.

Gallagher CJ, Salter MW: Differential properties of astrocyte calcium waves mediated by P2Y1 and P2Y2 receptors. J Neurosci 2003, 23: 6728–6739.PubMed

30.

Townsend-Nicholson A, King BF, Wildman SS, Burnstock G: Molecular cloning, functional characterization and possible cooperativity between the murine P2X4 and P2X4a receptors. Brain Res Mol Brain Res 1999, 64: 246–254. 10.1016/S0169-328X(98)00328-3PubMedCrossRef

31.

Jones CA, Chessell IP, Simon J, Barnard EA, Miller KJ, Michel AD, Humphrey PP: Functional characterization of the P2X(4) receptor orthologues. Br J Pharmacol 2000, 129: 388–394. 10.1038/sj.bjp.0703059PubMedCentralPubMedCrossRef

32.

Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P, Voigt M, Humphrey PP: International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 2001, 53: 107–118.PubMed

33.

Nasu-Tada K, Koizumi S, Tsuda M, Kunifusa E, Inoue K: Possible involvement of increase in spinal fibronectin following peripheral nerve injury in upregulation of microglial P2X4, a key molecule for mechanical allodynia. Glia 2006, 53: 769–775. 10.1002/glia.20339PubMedCrossRef

34.

Uhr M, Grauer MT, Holsboer F: Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003, 54: 840–846. 10.1016/S0006-3223(03)00074-XPubMedCrossRef

35.

Benjamin ER, Pruthi F, Olanrewaju S, Shan S, Hanway D, Liu X, Cerne R, Lavery D, Valenzano KJ, Woodward RM, Ilyin VI: Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR. Biochem Pharmacol 2006, 72: 770–782. 10.1016/j.bcp.2006.06.003PubMedCrossRef

36.

Yeung SY, Millar JA, Mathie A: Inhibition of neuronal KV potassium currents by the antidepressant drug, fluoxetine. Br J Pharmacol 1999, 128: 1609–1615. 10.1038/sj.bjp.0702955PubMedCentralPubMedCrossRef

37.

Chou CT, He S, Jan CR: Paroxetine-induced apoptosis in human osteosarcoma cells: activation of p38 MAP kinase and caspase-3 pathways without involvement of [Ca2+]i elevation. Toxicol Appl Pharmacol 2007, 218: 265–273. 10.1016/j.taap.2006.11.012PubMedCrossRef

38.

Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF: The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992, 52: 547–552.PubMedCrossRef

39.

Tsuda M, Inoue K, Salter MW: Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci 2005, 28: 101–107. 10.1016/j.tins.2004.12.002PubMedCrossRef

40.

Bardin L, Bardin M, Lavarenne J, Eschalier A: Effect of intrathecal serotonin on nociception in rats: influence of the pain test used. Exp Brain Res 1997, 113: 81–87. 10.1007/BF02454144PubMedCrossRef

41.

Crisp T, Stafinsky JL, Spanos LJ, Uram M, Perni VC, Donepudi HB: Analgesic effects of serotonin and receptor-selective serotonin agonists in the rat spinal cord. Gen Pharmacol 1991, 22: 247–251.PubMedCrossRef

42.

Jeong CY, Choi JI, Yoon MH: Roles of serotonin receptor subtypes for the antinociception of 5-HT in the spinal cord of rats. Eur J Pharmacol 2004, 502: 205–211. 10.1016/j.ejphar.2004.08.048PubMedCrossRef

43.

Deseure K, Breand S, Colpaert FC: Curative-like analgesia in a neuropathic pain model: Parametric analysis of the dose and the duration of treatment with a high-efficacy 5-HT(1A) receptor agonist. Eur J Pharmacol 2007,568(1–3):134–41. Epub 2007 Apr 22 10.1016/j.ejphar.2007.04.022PubMedCrossRef

44.

Sasaki M, Obata H, Saito S, Goto F: Antinociception with intrathecal alpha-methyl-5-hydroxytryptamine, a 5-hydroxytryptamine 2A/2C receptor agonist, in two rat models of sustained pain. Anesth Analg 2003, 96: 1072–1078. table of contents 10.1213/01.ANE.0000050560.15341.A8PubMedCrossRef

45.

Oatway MA, Chen Y, Weaver LC: The 5-HT3 receptor facilitates at-level mechanical allodynia following spinal cord injury. Pain 2004, 110: 259–268. 10.1016/j.pain.2004.03.040PubMedCrossRef

46.

Bardin L, Schmidt J, Alloui A, Eschalier A: Effect of intrathecal administration of serotonin in chronic pain models in rats. Eur J Pharmacol 2000, 409: 37–43. 10.1016/S0014-2999(00)00796-2PubMedCrossRef

47.

Sawynok J, Reid A: Spinal supersensitivity to 5-HT1, 5-HT2 and 5-HT3 receptor agonists following 5,7-dihydroxytryptamine. Eur J Pharmacol 1994, 264: 249–257. 10.1016/0014-2999(94)00465-XPubMedCrossRef

48.

Wang CZ, Namba N, Gonoi T, Inagaki N, Seino S: Cloning and pharmacological characterization of a fourth P2X receptor subtype widely expressed in brain and peripheral tissues including various endocrine tissues. Biochem Biophys Res Commun 1996, 220: 196–202. 10.1006/bbrc.1996.0380PubMedCrossRef

49.

Kim SH, Chung JM: An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50: 355–363. 10.1016/0304-3959(92)90041-9PubMedCrossRef

50.

Dixon WJ: Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980, 20: 441–462. 10.1146/annurev.pa.20.040180.002301PubMedCrossRef

51.

Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53: 55–63. 10.1016/0165-0270(94)90144-9PubMedCrossRef

52.

Yaksh TL, Jessell TM, Gamse R, Mudge AW, Leeman SE: Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo. Nature 1980, 286: 155–157. 10.1038/286155a0PubMedCrossRef

Title: Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief
Authors: Kenichiro Nagata
Toshiyasu Imai
Tomohiro Yamashita
Makoto Tsuda
Hidetoshi Tozaki-Saitoh
Kazuhide Inoue
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Molecular Pain / Issue 1/2009
Electronic ISSN: 1744-8069
DOI: https://doi.org/10.1186/1744-8069-5-20

At a glance: The STEP trials

Springer Medicine

Antidepressants inhibit P2X₄ receptor function: a possible involvement in neuropathic pain relief

Abstract

Background

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Genetic variation in the serotonin transporter gene (5-HTTLPR, rs25531) influences the analgesic response to the short acting opioid Remifentanil in humans

Different forms of glycine- and GABAA-receptor mediated inhibitory synaptic transmission in mouse superficial and deep dorsal horn neurons

Synaptically evoked glutamate transporter currents in Spinal Dorsal Horn Astrocytes

Dynamic regulation of the endocannabinoid system: implications for analgesia

Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli

Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology